 Oyster Point Pharma, Inc. OYST, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will be added to the Russell 2000, Russell 3000 and Russell Microcap Indexes, effective after the close of the U.S. markets on Monday, December 23, 2019. The Russell 2000 Index measures the performance of the small cap segment of the U.S. equity market. Membership in the Russell 2000 provides automatic inclusion in the appropriate growth and value style indexes. 